So why not tie the already 'advertised' yet remain

So why not tie the already 'advertised' yet remaining FY14 Bonus Milestones to pps performances and/or catalysts that equate to same, such a FMV or MC?

http://sludgereports.com/2014/10/11/ambs-the-...-been-set/

***** FY14 Bonus Milestones *****

1.) Nasdaq Uplist
30% Bonus = $35,437.50

2.) Eltoprazine US IND filed & Approved for LID
30% Bonus = $35,437.50

3.) LymPro Partner Validation of APP & CLIA Certification
25% Bonus = $29,531.24

4.) MANF ODD Apps Filed & Approved for OIA & RP
15% Bonus = $17,718.75

Will that do the trick for you to get this share price out of the proverbial "mud" and heading Northward? Instead of negatively commenting on what won't work, how about a little hard thinking and positively providing what you believe will?

You kow, shareprice - while considered the leading indicator, doesn't necessairly have to constitue the means by which leadership performance, accountability or incentives are based. Market Cap or FMV can easily be substiture for same, as the FY14 Bonus Milestones in and of themselves, are not and never were tied to shareholder valuation, or shareprice appreciation. This is just one of several dynamics we could pose that just might have a positive outcome, as very little has worked thus far to move us sustainably over $0.10 - even with 5 Star record breaking events such as we have had of late.